http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Xiaoling Che,Chunmei Yang,Liping Pan,Didi Gu,Guidong Dai,Jian Shu,Lu Yang 한국생체재료학회 2023 생체재료학회지 Vol.27 No.00
Background Non-intrusive imaging of gastrointestinal (GI) tract using computed tomography (CT) contrast agents is of the most significant issues in the diagnosis and treatment of GI diseases. Moreover, spectral CT, which can generate monochromatic images to display the X-ray attenuation characteristics of contrast agents, provides a better imaging sensitivity for diagnose inflammatory bowel disease (IBD) than convention CT imaging. Methods Herein, a convenient and one-pot synthesis method is provided for the fabrication of small-molecule lanthanide complex Holmium-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (Ho-DOTA) as a biosafe and high-performance spectral CT contrast agent for GI imaging with IBD. In vivo CT imaging was administered with both healthy mice and colitis mice induced by dextran sodium sulfate. Results We found that Ho-DOTA accumulated in inflammation sites of large intestines and produced high CT contrast compared with healthy mice. Both in vitro and in vivo experimental results also showed that Ho-DOTA provided much more diagnostic sensitivity and accuracy due to the excellent X-ray attenuation characteristics of Ho- DOTA compared with clinical iodinate agent. Furthermore, the proposed contrast media could be timely excreted from the body via the urinary and digestive system, keeping away from the potential side effects due to long-term retention in vivo. Conclusion Accordingly, Ho-DOTA with excellent biocompatibility can be useful as a potential high-performance spectral CT contrast agent for further clinical imaging of gastrointestinal tract and diagnosis of intestinal system diseases.
Wang Xiaoling,Shi Chunyan,Pan Wenbo,Lu Hai,Zhang Xiaoyu 한국화학공학회 2023 Korean Journal of Chemical Engineering Vol.40 No.7
Anaerobic/anoxia sequencing batch reactor (A/ASBR) system was used to analyze the quantity and composition of each branch of phosphorus accumulating organisms (PAOs) in activated sludge under different nitrate-nitrogen (NO 3 − -N) concentrations by using real-time quantitative polymerase chain reaction (PCR) technology. The study determined whether NO 3 − -N and its concentration change were the main driving factors for the variation of the quantity and composition of each branch of PAOs. The results show that with the increase of NO 3 − -N concentration from 10 mg/L to 40 mg/L, the number of bacterial 16S rRNA genes in the A/ASBR reactor changed slightly at 6.81×1011–7.53×1011 copies/g dry sludge. The number of PAO genes (Acc 16S rRNA) increased from 1.98×1011 to 3.53×1011 copies/g dry sludge, and the total number of ppk1 genes increased from 1.25×1011 to 3.59×1011 copies/g dry sludge. Additionally, the number of polyphosphate kinase (ppk) genes in Accumulibacter branch IA, IIC and IID was high, and the changes were positively related to the concentration of NO 3 − -N, while the number of branches in IIA, IIB and IIF was very low. The dosing concentration of NO 3 − -N was the main driving factor for the change of PAOs and their branch number and composition in the A/ASBR reactor.
Weihua Jia,Lichun Zhou,Xiaoling Liao,Yuesong Pan,Yongjun Wang 대한신경과학회 2015 Journal of Clinical Neurology Vol.11 No.4
Background and Purpose It is unclear whether postthrombolytic antiplatelet (AP) therapy after thrombolytic-related hemorrhage without extensive parenchymal involvement (THEPI) afects the clinical outcome. Tis study explored whether AP administration in patients with THEPI afects short- and long-term outcomes. Methods All of the data for this study were collected from the Trombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) registry. Patients with THEPI were assigned to either the AP (AP therapy should be commenced 24 h afer intravenous thrombolysis) or AP-naïve groups. THEPI was defned according to European-Australasian Acute Stroke Study II criteria. Te 90-day functional outcome, 7-day National Institutes of Health Stroke Scale (NIHSS) score, and 7-day and 90-day mortalities were compared between the AP and AP-naïve groups. Logistic regression analysis was used to evaluate the effects of AP therapy on the short- and long-term clinical outcomes. Results Of the 928 patients enrolled from those in the TIMS-China registry (n=1,440), 89 (9.6%) had nonsymptomatic intracerebral hemorrhage (ICH) within 24–36 h afer thrombolysis; 33 (37%) of these patients were given AP therapy (AP group) and 56 (63%) were not (APnaïve group). No significant differences were found for the risk of 7-day aggravated ICH (p=0.998), 7-day NIHSS score (p=0.5491), 7-day mortality [odds ratio (OR)=3.427; 95% confdence interval (95% CI)=0.344–34.160; p=0.294], 90-day mortality (OR=0.788, 95% CI=0.154– 4.040, p=0.775), or modifed Rankin score 5 or 6 at 90-days (OR=1.108, 95% CI=0.249–4.928, p=0.893) between the AP and AP-naïve groups afer THEPI. Conclusions Early administration of postthrombolytic AP therapy afer THEPI does not worsen either the short- or long-term outcome. AP therapy may be a reasonable treatment option for patients with THEPI to reduce the risk of ischemic stroke recurrence.
Zhao Jingyi,Li Bingyan,Ren Yongxia,Liang Tiansong,Wang Juan,Zhai Suna,Zhang Xiqian,Zhou Pengcheng,Zhang Xiangxian,Pan Yuanyuan,Gao Fangfang,Zhang Sulan,Li Liming,Yang Yongqiang,Deng Xiaoyu,Li Xiaole,C 생화학분자생물학회 2021 Experimental and molecular medicine Vol.53 No.-
Compelling evidence has indicated the vital role of lysine-specific demethylase 4 A (KDM4A), hypoxia-inducible factor-1α (HIF1α) and the mechanistic target of rapamycin (mTOR) signaling pathway in nasopharyngeal carcinoma (NPC). Therefore, we aimed to investigate whether KDM4A affects NPC progression by regulating the HIF1α/DDIT4/mTOR signaling pathway. First, NPC and adjacent tissue samples were collected, and KDM4A protein expression was examined by immunohistochemistry. Then, the interactions among KDM4A, HIF1α and DDIT4 were assessed. Gain- and loss-of-function approaches were used to alter KDM4A, HIF1α and DDIT4 expression in NPC cells. The mechanism of KDM4A in NPC was evaluated both in vivo and in vitro via RT-qPCR, Western blot analysis, MTT assay, Transwell assay, flow cytometry and tumor formation experiments. KDM4A, HIF1α, and DDIT4 were highly expressed in NPC tissues and cells. Mechanistically, KDM4A inhibited the enrichment of histone H3 lysine 9 trimethylation (H3K9me3) in the HIF1α promoter region and thus inhibited the methylation of HIF1α to promote HIF1α expression, thus upregulating DDIT4 and activating the mTOR signaling pathway. Overexpression of KDM4A, HIF1α, or DDIT4 or activation of the mTOR signaling pathway promoted SUNE1 cell proliferation, migration, and invasion but inhibited apoptosis. KDM4A silencing blocked the mTOR signaling pathway by inhibiting the HIF1α/DDIT4 axis to inhibit the growth of SUNE1 cells in vivo. Collectively, KDM4A silencing could inhibit NPC progression by blocking the activation of the HIF1α/DDIT4/mTOR signaling pathway by increasing H3K9me3, highlighting a promising therapeutic target for NPC.